Alzheimer’s disease, cerebrovascular disease, and the β-amyloid cascade
Open accessThe DOI matches its Crossref record; 211 of the 215 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD), considered the commonest neurodegenerative cause of dementia, is associated with hallmark pathologies including extracellular amyloid-β protein (Aβ) deposition in extracellular senile plaques and vessels, and intraneuronal tau deposition as neurofibrillary tangles. Although AD is usually categorized as neurodegeneration distinct from cerebrovascular disease (CVD), studies have shown strong links between AD and CVD. There is evidence that vascular risk factors and CVD may accelerate Aβ 40-42 production/ aggregation/deposition and contribute to the pathology and symptomatology of AD. Aβ deposited along vessels also causes cerebral amyloid angiopathy. Amyloid imaging allows in vivo detection of AD pathology, opening the way for prevention and early treatment, if disease-modifying therapies in the pipeline show safety and efficacy. In this review, we review the role of vascular factors and Aβ, underlining that vascular risk factor management may be important for AD prevention and treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, AD and cerebrovascular diseases may have common risk factors, such as hypertension, insulin resistance, diabetes, obesity, hyperhomocystinemia, hyperlipidemia, etc. (Craft, 2009; Fillit et al., 2008; Honjo et al., 2012; Purnell et al., 2009).”
From The Pathobiology of Vascular Dementia (2013) · cites this paper as Honjo et al., 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Retracted: ‘Clinical trials in Alzheimer’s disease’: immunotherapy approaches
Delrieu, J., Ousset, P. J., Caillaud, C., & Vellas, B. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07458.x · Cited by 139
RetractedExpert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · cited 1×
“…Attenuated Inversion Recovery imaging (FLAIR) to detect vasogenic edema and T2*-weighted gradient echo (GRE) to detect microbleeds are required at baseline and for safety monitoring as described in Sperling et al, 2011.218 conclusions Considerable progress has been made in AD-related research.”
BackgroundInfluentialImaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490
2013 Alzheimer's disease facts and figures
Alzheimer's Association, Thies, W., & Bleiler, L. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.02.003 · Cited by 3,328
Plasma Homocysteine as a Risk Factor for Dementia and Alzheimer's Disease
Seshadri, S., Beiser, A., Selhub, J., Jacques, P. F., Rosenberg, I. H., D'Agostino, R. B., Wilson, P. W. F., & Wolf, P. A. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011613 · Cited by 3,237
Research works printed but not linked: 8
- Pluta, 1999, Ischemic rats as a model in the study of the neurobiological role of human beta-amyloid peptide, Time-dependent disappearing diffuse amyloid plaques in brain. Neuroreport, 10, 3615
- Pettersen, 2008, Carotid artery bifurcation tortuosity as a possible contributor to substantia innominata atrophy and executive dysfunction in Alzheimer disease, Stroke, 39, 682
- 1994, CMAJ, 150, 899
- Huang, 2000, Alternate aggregation pathways of the Alzheimer beta-amyloid peptide, An in vitro model of preamyloid, 275, 36436
- 2000, Text revision, 135
- 2012, J Nucl Med, 53, 15N
- Roman, 1993, Vascular dementia: diagnostic criteria for research studies, Report of the NINDS-AIREN International Workshop. Neurology, 43, 250
- Neuropathology, 2001, Medical Research Council Cognitive Function and Aging Study, Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet, 357, 169
Cited by
The Pathobiology of Vascular Dementia
Iadecola, C. (2013) · Neuron · doi:10.1016/j.neuron.2013.10.008 · Cited by 1,857
“Furthermore, AD and cerebrovascular diseases may have common risk factors, such as hypertension, insulin resistance, diabetes, obesity, hyperhomocystinemia, hyperlipidemia, etc. (Craft, 2009; Fillit et al., 2008; Honjo et al., 2012; Purnell et al., 2009).”
How Does it STAC Up? Revisiting the Scaffolding Theory of Aging and Cognition
Reuter-Lorenz, P. A., & Park, D. C. (2014) · Neuropsychology Review · doi:10.1007/s11065-014-9270-9 · Cited by 948
“Moreover, there is an association of heart disease with amyloid deposition (Honjo et al. 2012) and major depression is associated with both a heightened white matter and amyloid burden (Brickman et al.”
BackgroundBlood–Brain Barrier Dysfunction as a Cause and Consequence of Alzheimer's Disease
Erickson, M. A., & Banks, W. A. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.135 · Cited by 572
The neuropathology and cerebrovascular mechanisms of dementia
Raz, L., Knoefel, J., & Bhaskar, K. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.164 · Cited by 470
“Notably, such remodeling leads to vascular disease and cerebral hypoperfusion associated with neuronal injury, structural and functional brain damage.(7) More specifically, neuroimaging findings indicate white matter hyperintensities, cerebrovascular lesions, and cerebral amyloid angiopathy (CAA).”
BackgroundNanoparticles for Brain Drug Delivery
Masserini, M. (2013) · ISRN Biochemistry · doi:10.1155/2013/238428 · Cited by 489
“BBB is a highly complex structure that tightly regulates the movement of ions of a limited number of small molecules and of an even more restricted number of macromolecules from the blood to the brain, protecting it from injuries and diseases.”
Background
Metadata
- Authors
- Honjo, K., Black, S. E., & Verhoeff, N. P. L. G.
- Affiliations
- Sunnybrook Health Science Centre (CA)
- University of Toronto (CA)
- Corresponding author
- Honjo, Kie
- Venue
- Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
- Publisher
- Cambridge University Press (CUP)
- Published
- 2012-11
- Volume
- 39
- Issue
- 6
- Pages
- 712-728
- ISSN
- 0317-1671 (ISSN-L)
- 2057-0155
- OpenAlex
- W2056384657
- Cited by
- 152
- References
- 215
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 5 · 2023: 8 · 2022: 9 · 2021: 9 · 2020: 13 · 2019: 11 · 2018: 7 · 2017: 14 · 2016: 18 · 2015: 15 · 2014: 17 · 2013: 21
- FWCI
- 1.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Alzheimer's Association
- Heart and Stroke Foundation of Canada
- Canadian Stroke Network
- Alzheimer Society
- University of Toronto
- Canadian Institutes of Health Research (13129)
- National Institute on Aging
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, cerebrovascular disease, amyloid-beta, cerebral amyloid angiopathy, vascular risk factors, amyloid plaques, cerebral vasculature, neurofibrillary tangles, amyloid imaging, dementia, disease-modifying therapy, Alzheimer's disease prevention
- MeSH terms
- Alzheimer Disease, Brain, Cerebrovascular Disorders, Humans, Radionuclide Imaging, Risk Factors, Amyloid beta-Peptides, Amyloid beta-Protein Precursor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Alzheimer’s disease, cerebrovascular disease, and the β-amyloid cascade. https://app.cochat.ai/papers/10.1017/s0317167100015547
- The paper
- Honjo, K., Black, S. E., & Verhoeff, N. P. L. G. (2012). Alzheimer’s disease, cerebrovascular disease, and the β-amyloid cascade. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. https://doi.org/10.1017/s0317167100015547
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.